Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2001;37:58-65

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kiarash, A.
Right arrow Articles by Carretero, O. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kiarash, A.
Right arrow Articles by Carretero, O. A.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*Protein
*UniGene
Related Collections
Right arrow Other hypertension

(Hypertension. 2001;37:58.)
© 2001 American Heart Association, Inc.


Scientific Contributions

Upregulated Expression of Rat Heart Intercellular Adhesion Molecule-1 in Angiotensin II– but Not Phenylephrine- Induced Hypertension

Arash Kiarash; Patrick J. Pagano; Mahmoud Tayeh; Nour-Eddine Rhaleb; Oscar A. Carretero

From the Hypertension and Vascular Research Division, Henry Ford Hospital, Detroit, Mich.

Correspondence to Patrick J. Pagano, PhD, Hypertension and Vascular Research Division, Henry Ford Hospital, 2799 West Grand Blvd, Detroit, MI 48202. E-mail ppagano1{at}hfhs.org

Abstract—Intercellular adhesion molecule-1 (ICAM-1), part of an immunoglobulin-like superfamily of adhesion molecules, is involved in several cardiovascular diseases. We investigated whether in vivo angiotensin II (Ang II) increases ICAM-1 in rats. Sprague-Dawley rats were infused with vehicle or Ang II (750 µg · kg-1 · d-1 SC) for 7 days. The contribution of Ang II receptors to ICAM-1 expression was investigated with a nonpeptide Ang II type 1 (AT1) receptor antagonist losartan (30 mg · kg-1 · d-1 in drinking water). Systolic blood pressure was elevated in Ang II–treated animals compared with sham-treated controls, and losartan blocked this increase. Tumor necrosis factor (TNF)-{alpha} (5 µg/kg IP bolus), a prototype inducer of ICAM-1, was administered as a positive control for ICAM-1 expression. After treatment, hearts were frozen in liquid nitrogen; homogenates were subjected to SDS-PAGE and immunoblotted with an anti-rat ICAM-1 monoclonal antibody. We detected a predominantly high-molecular-weight band in homogenates from non–TNF-{alpha}–treated rats, which was enhanced by 80±5% in TNF-{alpha}–treated rats. This band measured {approx}200 kDa, which is the molecular weight of ICAM-1 in its native dimer form. The same band was detected in homogenates from sham and Ang II–treated rats, with the latter showing a 150±10% increase in ICAM-1 versus sham controls. Immunoprecipitation of rat heart homogenates with anti-rat ICAM-1 antibody resulted in a dominant band of the same molecular weight as samples not treated with antibody. Losartan prevented enhanced expression of ICAM-1 in the presence of Ang II but had no effect on basal ICAM-1 expression. Phenylephrine, an {alpha}-agonist (3 mg · kg-1 · d-1 ), was infused for 1 week but had no effect on ICAM-1 expression, even though systolic blood pressure was elevated to the same level as in rats treated with Ang II. Thus, heart ICAM-1 expression is enhanced via AT1 receptor activation independent of hypertension. Ang II–induced ICAM-1 expression was time and dose dependent, with maximal expression occurring within 5 to 7 days at 100 to 750 µg/kg Ang II. Immunohistochemical staining demonstrated markedly increased ICAM-1 levels in the perivascular area in Ang II–infused rats. Monocyte/macrophage accumulation was significantly greater in Ang II–treated rat hearts than in sham-treated hearts (10±1; P<0.001; n=5). Thus during inflammation, overexpression of ICAM-1 may contribute to cardiovascular damage in diseases characterized by increased activity of the renin-angiotensin system.


Key Words: angiotensin II • cell adhesion molecules • hypertension, experimental • losartan • phenylephrine




This article has been cited by other articles:


Home page
HypertensionHome page
G. B. Silva and J. L. Garvin
Angiotensin II-Dependent Hypertension Increases Na Transport-Related Oxygen Consumption by the Thick Ascending Limb
Hypertension, December 1, 2008; 52(6): 1091 - 1098.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C.-X. Lin, N.-E. Rhaleb, X.-P. Yang, T.-D. Liao, M. A. D'Ambrosio, and O. A. Carretero
Prevention of aortic fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in angiotensin II-induced hypertension
Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1253 - H1261.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
H. Ando, J. Zhou, M. Macova, H. Imboden, and J. M. Saavedra
Angiotensin II AT1 Receptor Blockade Reverses Pathological Hypertrophy and Inflammation in Brain Microvessels of Spontaneously Hypertensive Rats
Stroke, July 1, 2004; 35(7): 1726 - 1731.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. Liu, F. Yang, X.-P. Yang, M. Jankowski, and P. J. Pagano
NAD(P)H Oxidase Mediates Angiotensin II-Induced Vascular Macrophage Infiltration and Medial Hypertrophy
Arterioscler Thromb Vasc Biol, May 1, 2003; 23(5): 776 - 782.
[Abstract] [Full Text] [PDF]